| HIV Infections
Prezcobix vs Stribild
Side-by-side clinical, coverage, and cost comparison for hiv infections.Deep comparison between: Prezcobix vs Stribild with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsStribild has a higher rate of injection site reactions vs Prezcobix based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Stribild but not Prezcobix, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Prezcobix
Stribild
At A Glance
Oral
Once daily
HIV-1 protease inhibitor
Oral
Once daily
Integrase inhibitor + CYP3A inhibitor + nucleoside/nucleotide analog reverse transcriptase inhibitors
Indications
- HIV Infections
- HIV Infections
Dosing
HIV Infections Adults and pediatric patients >=40 kg: 800 mg/150 mg once daily with food; pediatric patients 25 kg to <40 kg: 675 mg/150 mg once daily with food; pediatric patients 3 years and older, 15 kg to <25 kg: 600 mg/90 mg tablet for oral suspension dispersed in water, once daily with food.
HIV Infections One tablet (elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg, tenofovir disoproxil fumarate 300 mg) taken orally once daily with food in adults and pediatric patients 12 years of age and older with body weight at least 35 kg and creatinine clearance >=70 mL/min.
Contraindications
- Co-administration with alfuzosin
- Co-administration with carbamazepine, phenobarbital, or phenytoin
- Co-administration with colchicine in patients with renal and/or hepatic impairment
- Co-administration with rifampin
- Co-administration with lurasidone
- Co-administration with pimozide
- Co-administration with dronedarone
- Co-administration with ivabradine
- Co-administration with ranolazine
- Co-administration with ergot derivatives (dihydroergotamine, ergotamine, methylergonovine)
- Co-administration with St. John's wort (Hypericum perforatum)
- Co-administration with elbasvir/grazoprevir
- Co-administration with lomitapide
- Co-administration with lovastatin or simvastatin
- Co-administration with naloxegol
- Co-administration with sildenafil when used for pulmonary arterial hypertension
- Co-administration with orally administered midazolam or triazolam
- Coadministration with alfuzosin
- Coadministration with carbamazepine, phenobarbital, or phenytoin
- Coadministration with rifampin
- Coadministration with lurasidone or pimozide
- Coadministration with dihydroergotamine, ergotamine, or methylergonovine
- Coadministration with St. John's wort (Hypericum perforatum)
- Coadministration with lomitapide, lovastatin, or simvastatin
- Coadministration with sildenafil when used for pulmonary arterial hypertension
- Coadministration with triazolam or orally administered midazolam
Adverse Reactions
Most common (>=5%) Diarrhea, nausea, rash, headache, abdominal pain, vomiting
Postmarketing Redistribution of body fat, rhabdomyolysis (with HMG-CoA reductase inhibitors), crystal nephropathy, crystalluria, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, drug rash with eosinophilia and systemic symptoms
Most common (>=5%) Diarrhea, nausea, headache, fatigue
Serious Severe acute exacerbations of hepatitis B in coinfected patients, new onset or worsening renal impairment, lactic acidosis/severe hepatomegaly with steatosis, bone loss and mineralization defects, immune reconstitution syndrome
Postmarketing Allergic reactions including angioedema, lactic acidosis, hypokalemia, hypophosphatemia, dyspnea, pancreatitis, increased amylase, abdominal pain, hepatic steatosis, hepatitis, increased liver enzymes, rash, rhabdomyolysis, osteomalacia, muscular weakness, myopathy, acute renal failure, renal failure, acute tubular necrosis, Fanconi syndrome, proximal renal tubulopathy, interstitial nephritis, nephrogenic diabetes insipidus, renal insufficiency, increased creatinine, proteinuria, polyuria, asthenia
Pharmacology
Darunavir is an HIV-1 protease inhibitor that selectively inhibits cleavage of HIV-1 Gag-Pol polyproteins in infected cells, preventing formation of mature virus particles; cobicistat is a mechanism-based CYP3A inhibitor that increases darunavir systemic exposure without intrinsic antiviral activity.
STRIBILD is a fixed-dose combination of elvitegravir (an integrase strand transfer inhibitor), cobicistat (a CYP3A inhibitor that boosts elvitegravir levels), emtricitabine (a nucleoside reverse transcriptase inhibitor), and tenofovir disoproxil fumarate (a nucleotide reverse transcriptase inhibitor).
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Prezcobix
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (1/12) · Qty limit (11/12)
Stribild
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Prezcobix
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (2/8)
Stribild
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (3/8) · Qty limit (5/8)
Humana
Prezcobix
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Stribild
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$0
Gilead Advancing Access Patient Assistance Program/Medication Assistance Program (PAP/MAP)Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
PrezcobixView full Prezcobix profile
StribildView full Stribild profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.